MedSci and Actelion Pharmaceuticals Enter Strategic Collaboration to Advance Rare Disease Awareness and Treatment in China

MedSci and Actelion Pharmaceuticals Trading Shanghai Co., Ltd., a subsidiary of Janssen Pharmaceuticals under Johnson & Johnson, signed an in-depth academic strategic cooperation agreement.

November 202118Day,Shanghai,MedSci has signed a partnership with Actelion Pharmaceuticals Trading Shanghai Co., Ltd., a subsidiary of Janssen Pharmaceuticals under Johnson & Johnson.Deep AcademiaStrategyCooperation Agreement。Both parties announcedOn the premise of meeting their respective strategic development concepts, a strategic partnership has been formed to jointly explore new business development models, and enhance and promote the level of disease awareness in China's rare disease field.Diagnosis and TreatmentLevel up.

Both parties adhere to the basic principles of "legality and compliance, complementary advantages, mutual benefit, and shared risks."MedSci and Actelion Pharmaceuticals Trading Shanghai Co., Ltd., a subsidiary of Janssen Pharmaceuticals under Johnson & Johnson, have agreed to leverage their respective resource advantages and comparative advantages. The collaboration includes, but is not limited to, the establishment of nationwide academic platforms in the field of pulmonary arterial hypertension, referral model design, virtual representative empowerment, digital patient-physician education, and market information research in China.In-depth cooperation in the field。

Pulmonary Hypertension(Pulmonary Hypertension, PH) refers to a condition caused by various heterogeneous diseases (etiologies) and different pathogenic mechanisms in the lungs.Blood VesselStructural or functional changes lead to clinical and pathophysiological syndromes characterized by increased pulmonary vascular resistance and pulmonary artery pressure, which subsequently develop into right-sided...Heart FailureExhaustion leading to death.Because the prognosis is similar to that of certain cancers, some people call it "Cardiovascular"Cancer in Diseases".

Actelion Pharmaceuticals Trading Shanghai Co.,Ltd. is the market leader in the field of pulmonary arterial hypertension (PAH), with a comprehensive range of PAH treatment products covering the full spectrum of WHO functional class II to IV diseases, including oral, inhaled, and intravenous formulations.In 2019,Actelion Pharmaceuticals Trading Shanghai Co.,Ltd. Announces Bosentan Dispersible Tablets Receive Approval from National Medical Products AdministrationManagementApproved by the Bureau for treatmentChildrenPulmonary Arterial Hypertension. Bosentan Dispersible Tablets have thus become the first approved medication in China for pediatric patients with pulmonary arterial hypertension.

During the past two decades, Actelion's products have significantly helped a large number of patients with pulmonary arterial hypertension improve their prognosis and quality of life. Janssen has now incorporated pulmonary arterial hypertension into its key therapeutic areas to consolidate and expand Actelion's leading position in this field.

MedSci is a well-known professional clinical research platform in China, with strong academic and scientific research service capabilities.Accumulation, capable of providing crucial external resources and intellectual support. MedSci, an early participant in pharmaceutical digitalization, has continuously explored and expanded its presence in the field for nearly 20 years, achieving numerous accomplishments. It has grown into a leading digital platform for clinical research and medical academic dissemination, serving hundreds of well-known pharmaceutical and device companies both in China and internationally.ComprehensiveHealthcare Digital Marketing Solutions.

This DepthAcademic CooperationSigning willAccelerate PromotionIntroduced in ChinaPulmonary HypertensionTreatment Plan,ServiceVastChinese patients. Provide more localized clinical evidence for Chinese clinical practice.CommonPromote awareness and diagnostic treatment levels in the field of rare diseases. (BioValley bioon）

 ----

About Actelion Pharmaceuticals Trading Shanghai Co., Ltd. under Janssen Pharmaceuticals of Johnson & Johnson

In June 2017, Actelion joined Janssen Pharmaceuticals under Johnson & Johnson. Actelion is headquartered in Allschwil, Basel-Stadt, Switzerland. As a market leader in the field of pulmonary arterial hypertension (PAH), Actelion’s PAH treatment portfolio covers the full spectrum of the disease from WHO functional class II to IV, including oral, inhaled, and intravenous formulations. Over the past two decades, Actelion's products have significantly improved outcomes and quality of life for a wide range of PAH patients. Janssen has now incorporated PAH as a key therapeutic area to consolidate and expand Actelion’s leading position in this field.

About MedSci:

MedSci (MedSci) is a comprehensive Internet platform for doctors, applicationBig DataLinking doctors, patients, pharmaceutical and medical device companies, etc. through artificial intelligence technology to providePrecisionDigital Medical Communication Solutions: Optimizing the Healthcare Ecosystem, Improving Medical Quality, and Creating a Better Healthy Life.

MedSci's main products include digital medical communication and digital clinical research, covering categories such as clinical research, physician career development, multi-channel academic communication, and smart healthcare. At the digital clinical research level, MedSci provides comprehensive solutions for clinical research, reducing costs and improving quality through digital technology. In terms of digital medical communication, MedSci delivers professional medical content and precise, integrated communication strategies, ensuring the latest technologies and knowledge are accurately conveyed to target physicians.